# Robert Chu

> Robert Chu is the co-founder and CEO of Embleema, a New York-based clinical research platform that collects and generates regulatory-grade evidence to accelerate precision medicine. He founded the company in 2017 after nearly three decades in enterprise technology and life sciences data, including roles as Senior Vice President of Global Technology Solutions at IQVIA (formerly QuintilesIMS), where he ran a 1,400-person, $800M SaaS business, and prior leadership positions at IMS Health in France, China, and Asia Pacific, following 15+ years at IBM. Trained as an engineer at Ecole Polytechnique in Paris, he now works at the intersection of patient consent, blockchain, and clinical data collection, with Embleema partnering with pharma sponsors and the FDA on real-world evidence workflows.

- **Role:** Co-Founder & CEO at Embleema
- **Organizations:** Embleema, IQVIA, IMS Health, IBM
- **Nationality:** French
- **Education:** Master's in Engineering, Ecole Polytechnique, Master's in Computer Sciences, Ecole Nationale Superieure des Telecommunications (Telecom Paris)
- **Known for:** Co-founded and continues to lead Embleema, a clinical research platform focused on regulatory-grade real-world evidence, Ran a 1,400-person, $800M SaaS business as SVP of Global Technology Solutions at IQVIA, Built and managed data networks in 20+ countries across the U.S., Europe, and Asia

## Career timeline

- **1990** — Joined IBM in Europe and the US, spending 15+ years in technical and management roles
- **2007** — Joined IMS Health France in June
- **2011** — Became General Manager of IMS Health France
- **2013** — Moved to Shanghai to run IMS Health's Asia Pacific and China operations
- **2015** — Promoted to Senior Vice President, Global Technology Solutions at IMS Health / QuintilesIMS (later IQVIA), managing 1,400 employees and an $800M SaaS business
- **2017** — Co-founded Embleema in New York with Nicolas Schmidt
- **2018** — Embleema emerged from stealth with a blockchain-based patient health record system
- **2019** — Embleema closed Series A round (approx. $3.6M)
- **2024** — Embleema reported approximately $3.1M in revenue with a ~23 person team

## Achievements

- Co-founded and continues to lead Embleema, a clinical research platform focused on regulatory-grade real-world evidence
- Ran a 1,400-person, $800M SaaS business as SVP of Global Technology Solutions at IQVIA
- Built and managed data networks in 20+ countries across the U.S., Europe, and Asia
- Grew Embleema to ~$3.1M revenue with a small team of ~23-29 people

## Latest updates

- **2024-01** — Embleema reported ~$3.1M revenue with a 23-person team, per public founder profile aggregators.

## Links

- Website: https://embleema.com
- LinkedIn: https://www.linkedin.com/in/robert-chu-06204a5a
- Twitter/X: https://twitter.com/Embleema
- Facebook: https://facebook.com/embleema/

---

Profile page: https://yespress.io/robert-chu
Published by YesPress — https://yespress.io
Last updated: 2026-07-08